In a report published by Dawson James, analyst Robert M. Wasserman reiterated a Buy rating and $6.00 price target on Agenus, Inc. AGEN
Dawson James reported that, “Key developments for the fourth quarter for Agenus included the November publication of the second complete results from the Phase 3 trial of GSK's malaria vaccine candidate and the start of a Phase 2 multicenter study of HerpV for the treatment
of genital herpes in HSV-2 positive subjects. Subsequent to year-end, Agenus completed enrollment in this Phase 2 HerpV viral shedding study, with results expected to be released by the end of this year.”
Shares of Agenus, Inc. closed at $4.46 on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in